Obsessive-Compulsive Disorder (OCD) Clinical Trial
Official title:
Neural Predictors and Neural Changes Associated With Cognitive Behavior Therapy for Obssesive Compulsive Disorder
The goals of the project are 1) to understand what are the neural mechanisms involved in the psychological treatment of obsessive-compulsive disorder (OCD) in children/adolescents and adults, 2) to assess potential differences in the neural mechanisms involved in the psychological treatment of OCD between children/adolescents and adults, and 3) to assess the effectiveness of intensive CBT for children/adolescents and adults with OCD.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | September 1, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 8 Years to 60 Years |
Eligibility | Inclusion Criteria: (same for Study 1 and Study 2): 1. Principal diagnosis of OCD; 2. Y-BOCS or CYBOCS = 16). 3. No current psychotropic medication (except benzodiacepines for sleep). 4 ) Age between 8 and 17 years (Study 1) and between 18 and 60 years (Study 2). Exclusion Criteria: (same for Study 1 and Study 2 1. Current major depression or current/past psychosis, bipolar disorder or substance abuse. 2. Developmental disorders (including autistic spectrum disorders). 3. To be pregnant or during breastfeeding 4. Current CBT; nt. 5. Any severe medical disorder ; 6. Any contraindication for neuroimaging |
Country | Name | City | State |
---|---|---|---|
Spain | IDIBAPS | Barcelona | |
Spain | IDIBELL | L'Hospitalet de Llobregat | Barcelona |
Spain | FIDMAG Germanes Hospitalàries | Sant Boi De Llobregat | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Institut d'Investigació Biomèdica de Bellvitge | FIDMAG Germanes Hospitalàries, Institut d'Investigacions Biomèdiques August Pi i Sunyer |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Yale-Brown Obsessive-Compulsive Scale | The Yale-Brown Obsessive-Compulsive Scale evaluates the severity of Obsessive Compulsive Disorder symptoms in adults. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms) (total range, 0 to 40), with separate subtotals for severity of obsessions and compulsions. | Change from baseline to post-treatment (1 month) | |
Primary | Children´s Yale-Brown Obsessive-Compulsive Scale | The Children´s Yale-Brown Obsessive-Compulsive Scale evaluates the severity of Obsessive Compulsive Disorder symptoms in children/adolescents. The severity of the obsessions is rated on five Severity Items for Obsessions. Each of these five items is rated on a 5-point, ordinal scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = extreme. These values are anchored by a description for each score. The Obsessions Severity Score is obtained by adding the scores for items 1 through 5 (range = 0 to 20).
There are five comparable Severity Items for Compulsions (items 6 through 10), which are also scored from 0 to 4. The Compulsions Severity Score is obtained by adding the scores of items 6 through 10 (range = 0 to 20). Summing the scores for all 10 items yields the CY-BOCS Total score (range = 0 to 40). |
Change from baseline to post-treatment (1 month) | |
Secondary | Obsessive-Compulsive Inventory-Revised | Obsessive-Compulsive Inventory-Revised is a self-report scale for assessing symptoms of Obsessive-Compulsive Disorder in adults. It consists of 18 questions that a person endorses on a 5-point Likert scale. Scores are generated by adding the item scores. The possible range of scores is 0-72. Mean score for persons with OCD is 28.0 (SD = 13.53). Recommended cutoff score is 21, with scores at or above this level indicating the likely presence of OCD. | Change from baseline to post-treatment (1 month) | |
Secondary | Obsessive Compulsive Inventory-Child Version | Questionnaire assessing severity of obsessive-compulsive disorder symptoms children/adolescents. It is a 21-item self-report questionnaire, based on the 42-item adult version. Items are scored on a 3-point Likert scale. The measure is designed to evaluate obsessive-compulsive disorder in children between 7 and 17 years old. The total ranges from 0 to 42 points. | Change from baseline to post-treatment (1 month) | |
Secondary | Children's Depression Inventory | The Children's Depression Inventory is a psychological assessment that rates the severity of symptoms related to depression or dysthymic disorder in children and adolescents. It is a 27-item scale that is self-rated and symptom-oriented. The 27 items on the assessment are grouped into five major factor areas. Patients rate themselves based on how they feel and think, with each statement being identified with a rating from 0 to 2. | Change from baseline to 1 month. | |
Secondary | Spence Children's Anxiety Scale | The Spence Children's Anxiety Scale is a psychological questionnaire designed to identify symptoms of various anxiety disorders, specifically social phobia, obsessive-compulsive disorder, panic disorder/agorophobia, and other forms of anxiety, in children and adolescents between ages 8 and 15. There are 45 questions evaluating the frequency of certain anxiety symptoms, measured on a 0-3 scale from "never," "sometimes," often," to "always." A maximum score of 114 is possible on the child and parent-reported, and there are six subscales calculated within the final score. The total score is interpreted in different ways depending on the child's age and gender. For boys and girls ages 8-11, a total score of 40 and above or 50 and above is classified as elevated levels of anxiety, respectively. For boys and girls ages 12-15, a total score of 33 and above or 39 and above is classified as elevated, respectively. | Change from baseline to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01949753 -
Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT02267629 -
Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT02867449 -
Metacognitive Therapy for Obsessive-Compulsive Disorder
|
N/A | |
Completed |
NCT01368510 -
Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder
|
N/A | |
Not yet recruiting |
NCT05422469 -
OCD Biomarker Survey Employing sEEG and Stimulation: The OBSESS Trial
|
N/A | |
Active, not recruiting |
NCT03300947 -
Psilocybin for Treatment of Obsessive Compulsive Disorder
|
Phase 1 | |
Recruiting |
NCT02773082 -
Reclaim™ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)
|
N/A | |
Not yet recruiting |
NCT06360991 -
DBS for Treatment-resistant Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT03605316 -
Deep Electrical Neuromodulation in Obsessive-compulsive Disorder
|